Cargando…

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma

SIMPLE SUMMARY: The identification of new pharmacological combinations with synergistic effect in multiple myeloma is highly relevant since this is, for the moment, an incurable disease. The high expression of Proviral Insertion site for Moloney murine leukemia virus (PIM) kinases, especially PIM2,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paíno, Teresa, González-Méndez, Lorena, San-Segundo, Laura, Corchete, Luis A., Hernández-García, Susana, Díaz-Tejedor, Andrea, Algarín, Esperanza M., Mogollón, Pedro, Martín-Sánchez, Montserrat, Gutiérrez, Norma C., Mateos, María-Victoria, Garayoa, Mercedes, Ocio, Enrique M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598606/ https://www.ncbi.nlm.nih.gov/pubmed/32987735 http://dx.doi.org/10.3390/cancers12102743

Ejemplares similares

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
por: Mogollón, Pedro, et al.
Publicado: (2019)

PB1778: PAN-PIM KINASE INHIBITOR PIM447 SHOWS SUPERIOR ANTI-LEUKEMIC EFFECT IN ACUTE ERYTHROID LEUKEMIA
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

PB1814: THERAPEUTIC POTENTIAL AND STRATEGIES OF PIM447, A PAN-PIM INHIBITOR, TARGETING REFRACTORY MYELOID LEUKEMIA WITH KIT-DRIVEN T(8/21)
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study
por: Chen, Qingqing, et al.
Publicado: (2019)

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
por: Algarín, Esperanza M., et al.
Publicado: (2021)

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447
por: Peters, Tara L., et al.
Publicado: (2016)

Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas
por: Kreuz, S., et al.
Publicado: (2015)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Linac4 PIMS
por: Pantelia, Anna
Publicado: (2014)

The role of PIM1/PIM2 kinases in tumors of the male reproductive system
por: Jiménez-García, Manuel Pedro, et al.
Publicado: (2016)

Multicenter validation of PIM3 and PIM2 in Brazilian pediatric intensive care units
por: Genu, Daniel Hilário Santos, et al.
Publicado: (2022)

Dama de Porto Pim /
por: Tabucchi, Antonio, 1943-2012
Publicado: (1984)

El Pim-pam-pum
por: Ionesco, Eugène

Dama de Porto Pim
por: Tabucchi, Antonio 1943-
Publicado: (1997)

PIM Kinases in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2021)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus
por: Jiménez-García, Manuel-Pedro, et al.
Publicado: (2017)

Crosslinking of Branched PIM-1 and PIM-Py Membranes for Recovery of Toluene from Dimethyl Sulfoxide by Pervaporation
por: Aloraini, Sulaiman, et al.
Publicado: (2023)

P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA
por: Diaz-Tejedor, A., et al.
Publicado: (2022)

Association between Potentially Inappropriate Medication (PIM) Use and Risk of Hospitalization in Older Adults: An Observational Study Based on Routine Data Comparing PIM Use with Use of PIM Alternatives
por: Endres, Heinz G., et al.
Publicado: (2016)

Overexpression of Pim-1 in bladder cancer
por: Guo, Shengjie, et al.
Publicado: (2010)

Targeting the Pim kinases in multiple myeloma
por: Keane, N A, et al.
Publicado: (2015)

Role of PIM2 in allergic asthma
por: Du, Wei, et al.
Publicado: (2017)

A review on PIM kinases in tumors
por: Arrouchi, Housna, et al.
Publicado: (2019)

PIM Kinase as an Executional Target in Cancer
por: Zhang, Xinning, et al.
Publicado: (2018)

An adult presentation consistent with PIMS-TS
por: Jones, Imogen, et al.
Publicado: (2020)

Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion
por: Santio, Niina M, et al.
Publicado: (2010)

PIM1 polymorphism and PIM1 expression as predisposing factors of esophageal squamous cell carcinoma in the Asian population
por: Wu, Yuan-Bo, et al.
Publicado: (2016)

High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms
por: Motylewska, Ewelina, et al.
Publicado: (2020)

Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics
por: Wang, Yixin, et al.
Publicado: (2021)

Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities
por: Sawaguchi, Yuichi, et al.
Publicado: (2021)

Potentially inappropriate medications (PIMs): frequency and extent of GP-related variation in PIMs: a register-based cohort study
por: Ribe, Anette Riisgaard, et al.
Publicado: (2021)

COVID-19 and PIMS—Two Different Entities, but the Same Trigger
por: Meliț, Lorena Elena, et al.
Publicado: (2022)

Linac4 PIMS Construction and First Operation
por: Wegner, Rolf, et al.
Publicado: (2017)

Casuïstiekprijs H&W voor Pim Keurlings
por: Smeele, Ivo
Publicado: (2021)

The Role of PIM Kinases in Pediatric Solid Tumors
por: Julson, Janet Rae, et al.
Publicado: (2022)

PIMS/MIS-C in der Omicron-Welle
por: Kerbl, Reinhold
Publicado: (2022)

Targeting PIM Kinases to Improve the Efficacy of Immunotherapy
por: Clements, Amber N., et al.
Publicado: (2022)

Correction to ‘In vivo analysis of Pim-1 deficiency’
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_joj21ot24qjtrcjtpurqsa9aoo